AtheroNova Inc. Announces New Trading Symbol

IRVINE, CA--(Marketwire - May 25, 2010) - AtheroNova Inc. (OTCBB: TRHI) (“AtheroNova”) announced it has commenced trading under its new symbol AHRO.OB (OTCBB: AHRO) as of the opening of the market today.

Along with the symbol change, the Company filed its preliminary 14C information statement with the Securities and Exchange Commission on May 24, 2010 in expectation of completing its 1-for-200 reverse split of its common stock by the end of June. The reverse split will result in the Company having approximately 22,680,127 shares outstanding upon completion of the split (32,544,574 on an as-converted basis for all currently outstanding options, warrants and convertible debt). “We are pleased to have completed these steps in the merger and financing consummated by the company on May 13th,” stated Mark Selawski, the company’s Chief Financial Officer. “We look forward to a timely conclusion to the capital restructuring of the Company in the coming days,” he added.

AtheroNova Inc. (formerly Trist Holding Inc.) (“Trist”) completed its merger transaction with Z&Z Holdings, Inc. (“Z&Z”) on May 13, 2010, completed a capital raise transaction through the placement of $1.5 million in 2.5% Senior Secured Convertible Notes and put in place a senior management team with many years experience in the healthcare field. AtheroNova Operations, Inc., formerly Z&Z, is a healthcare company that has developed certain intellectual property to address atherosclerosis and the related health risks of the disease.

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The company is preparing to commence a second animal study at the Cedars-Sinai Division of Cardiology in conjunction with UCLA to validate the findings of its initial study and prepare for human trials. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade and over-the-counter grade products, for the treatment of atherosclerosis.

Additional information about the merger, capital raise transaction and AtheroNova Operations, Inc. (formerly Z&Z Medical Holdings, Inc.), can be found in AtheroNova’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2010.

About AtheroNova Inc. and AtheroNova Operations, Inc.

Prior to the closing, AtheroNova was a public “shell” company with nominal assets whose sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.

Effective as of the closing, AtheroNova, through its wholly-owned subsidiary AtheroNova Operations, Inc. will continue to be a development stage company, developing products to address the treatment of atherosclerosis through the use of natural compounds and their derivatives.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding completion of AtheroNova’s restructuring, commencement of the second animal trial and the development of applications for AtheroNova’s compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova’s filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.